lundi 16 novembre 2026
RechercherExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
News articleYahoo Finance· November 12, 2026

Scribe Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights

View original at finance.yahoo.com
“Cash, cash equivalents, and marketable securities of $174.2 million as of September 30, 2026, provide funding into the first half of 2029”
Verbatim excerpt from the source · Yahoo Finance · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Current LDL-C lowering therapies are limited by poor persistence and adherence, with studies showing 50% to 70% of patients discontinue treatment within one year.

    60% confidence
  • Q3 was a period of continued execution for Scribe, marked by the completed IPO and the expansion of the Sanofi collaboration to include the epigenetic silencing technology, which strengthen the Company's foundation for translating its technologies into medicines.

    60% confidence
  • Individuals with naturally occurring PCSK9 loss-of-function variants have been reported to have 28% lower mean LDL-C levels and up to 88% lower coronary heart disease risk; STX-1150 aims to mimic this protection and could shift LDL-C management from chronic treatment to long-term prevention.

    60% confidence
  • Cash, cash equivalents and marketable securities of $174.2 million as of September 30, 2026 provide funding into the first half of 2029.

    60% confidence
  • Initial clinical data from the STX-1150 Phase 1 trial are expected in the first half of 2027.

    60% confidence

Cité dans ces articles de Via News

Scribe Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights: Source | Via News | fr.via.news